Trial reportIntegrative cancer therapies
A Randomized, Controlled, Parallel-Group, Trial on the Long-term Effects of Melatonin on Fatigue Associated With Breast Cancer and Its Adjuvant Treatments.
Trial report in Integrative cancer therapies. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 5 syntheses or guidelines pooled it, 33 citations in OpenAlex.
- Exploring the impact of melatonin on cancer-related fatigue: a dose-response meta-analysis with GRADE evidence evaluation.BMC cancer · 2026Pooled it
- Pooled it
- Melatonin in cancer treatment.The Cochrane database of systematic reviews · 2025Pooled it
- Survival benefits of propofol-based versus inhalational anesthesia in non-metastatic breast cancer patients: a comprehensive meta-analysis.Scientific reports · 2024Pooled it
- Efficacy of Melatonin in Alleviating Radiotherapy-Induced Fatigue, Anxiety, and Depression in Breast Cancer Patients: A Systematic Review and Meta-Analysis.Integrative cancer therapiesPooled it
- Melatonin supplementation for quality of life in older patients with advanced cancer: a randomized controlled trial.BMC geriatrics · 2025Trial
- Efficacy of Melatonin in Alleviating Radiotherapy-Induced Fatigue, Anxiety, and Depression in Breast Cancer Patients: A Randomized, Triple-Blind, Placebo-Controlled Trial.Integrative cancer therapiesTrial
- Effectiveness of Shuanghuang Yangxue Decoction for Treating Cancer-Related Anemia With Serum Iron Deficiency in Lung Cancer Patients: A Randomized Clinical Trial.Integrative cancer therapiesTrial
- Reactive Oxygen Species in Breast Cancer: From Redox Dysregulation to ROS-Responsive Therapeutics.Cell biochemistry and function · 2026Review
- Radiomitigators: Breakthroughs in Post-Radiation Recovery.Antioxidants (Basel, Switzerland) · 2026Review
- Melatonin at the Crossroads of Oxidative Stress, Immunity, and Cancer Therapy.Antioxidants (Basel, Switzerland) · 2026Review
- Artificial intelligence in breast surgery: Current applications, challenges, and future perspectives.The Journal of international medical research · 2026Review
- Melatonin for the Management of Cancer-Related Fatigue in Breast Cancer: An Integrative Review.Journal of the advanced practitioner in oncology · 2026Review
- Therapeutic Potential of Melatonin in Gastrointestinal Cancers: Molecular Mechanisms, Preclinical Evidence and Clinical Implications.Journal of pineal research · 2026Review
- Restoration of melatonin rhythms reduces tumour-promoting inflammation in oesophageal cancer survivors: a prospective cohort study.Frontiers in immunology · 2026Article
- Knowledge, attitude and practice toward postoperative upper limb exercise among patients undergoing axillary lymph node dissection for breast cancer.BMC public health · 2025Article
- ERK-driven autophagy enhances synergy of eribulin and cisplatin in triple-negative breast cancer.Oncology letters · 2025Article
- Impact of Chemotherapy on Motor-Cognitive Dual-Task Performance in Strength and Mobility Tests.Healthcare (Basel, Switzerland) · 2025Article
- Evaluation of 30-day mortality rate following intravenous systemic anticancer therapy: a retrospective analysis.BMC cancer · 2025Article
- Melatonin: a natural guardian in cancer treatment.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveCancer related fatigue is a distressing condition and correlated with decrease in quality of life of patients with malignant conditions. In continuation of our previous research, we assessed long term anti-fatigue effects of melatonin in patients with the breast cancer. MATERIAL AND
methodsIn this clinical trial, 92 breast cancer patients were randomly assigned to receive either melatonin (18 mg/day) or placebo from 1 week before the adjuvant treatments until 2 years after their completion. The levels of fatigue were assessed before and after intervention using Brief Fatigue Inventory (BFI) and were compared at a significance level of
resultsThe BFI scores were similar between the 2 groups at the baseline (placebo group: 5.56 ± 1.59 and melatonin group: 5.72 ± 1.68,
conclusionLong-term usage of melatonin even after completion of adjuvant therapies in women with breast cancer decreased the levels of fatigue associated with the malignant condition and its treatments. THE TRIAL REGISTRY NAME AND URL, AND REGISTRATION NUMBER: Iranian Registry of Clinical Trials, https://en.irct.ir/trial/62267, IRCT20180426039421N3.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.